Limbic seizures induce P-glycoprotein in rodent brain: Functional implications for pharmacoresistance

Journal of Neuroscience

Volumn 22, Issue 14, 2002, Pages 5833-5839

  Rizzi, Massimo ^a   Caccia, Silvio ^a   Guiso, Giovanna ^a   Richichi, Cristina ^a   Gorter, Jan A ^b   Aronica, Eleonora ^c   Aliprandi, Marisa ^a   Bagnati, Renzo ^a   Fanelli, Roberto ^a   D'Incalci, Maurizio ^a   Samanin, Rosario ^a   Vezzani, Annamaria ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anticonvulsant drugs; Epilepsy; Mdr; P glycoprotein; Rat; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE PERMEABILITY; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DRUG RESISTANCE; ENTORHINAL CORTEX; EPILEPTOGENESIS; HYDROPHOBICITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RISK FACTOR; SYNAPTIC TRANSMISSION;

EID: 0037101618     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-14-05833.2002     Document Type: Article

References (44)

1. Bendotti C, Vezzani A, Serafini R, Servadio A, Rivolta R, Samanin R (1991) Increased preproneuropeptide Y mRNA in the rat hippocampus during the development of hippocampal kindling: Comparison with the expression of preprosomatostatin mRNA. Neurosci Lett 132: 175-178.
2. Cockerell OC, Johnson AL, Goodridge DMG, Sander JWAS, Shorvon SD (1995) The remission of epilepsy: Results from the rational General Practise Study of Epilepsy. Lancet 346:140-144.
3. Collaborative Group for the Study of Epilepsy (1992) Prognosis of epilepsy in newly referred patients: A multicenter prospective study of the effects of monotherapy on the long-term onset of epilepsy. Epilepsia 93:45-51.
4. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
5. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE (1989) The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9:1346-1350.
6. Dantzig AH, Law KL, Cao J, Starling JJ (2001) Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 8:39-50.
7. Desrayaud S, De Lange ECM, Lemaire M, Bruelisauer, De Boer AG, Breimer DD (1998) Effect of the mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent in mice. J Pharmacol Exp Ther 285:438-443.
8. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171.
9. Fountain NB, Bear J, Bertram EH, Lothman EW (1998) Responses of deep entorhinal cortex are epileptiform in an electrogenic rat model of chronic temporal lobe epilepsy. J Neurophysiol 80:230-240.
10. Frey HH, Janz D (1985) Antiepileptic drugs. In: Handbook of Experimental Pharmacology 74 (Frey H-H, Janz D, eds), pp 351-419, 479-506. Berlin: Springer.
11. Golden PL, Pardridge WM (1999) P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res 819: 143-146.
12. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gadzar A, Pirker R, Green A, Crist W, Brodeur GM (1989) Expression of multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124.
13. Gorter JA, van Vliet EA, Aronica E, Lopes da Silva FH (2001) Progression of spontaneous seizures after status epilepticus is associated with mossy fibre sprouting and extensive bilateral loss of hilar parvalbumin and somatostatin-immunoreactive neurons. Eur J Neurosci 13:657-669.
14. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
15. Hauser WA, Hesdorffer DC (1990) Epilepsy: Frequency, Causes, and Consequences, pp 197-243. Landover, MD: Epilepsy Foundation of America.
16. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
17. Juliano RL, Ling V (1998) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
18. Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A (1999) Tuberous sclerosis with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 21:731-734.
19. Lemaire M, Bruelisauer A, Guntz P, Sato H (1996) Dose-dependent brain penetration of SDZ PSC833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol 38:481-486.
20. Liu H, Delgado M, Forman LJ, Eggers CM, Montoya JL (1993) Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiodide-array detection. J Chromatogr 616:105-115.
21. Lombardo AJ, Kuzniecky R, Powers RE, Brown GB (1996) Altered brain sodium channel transcript levels in human epilepsy. Mol Brain Res 35:84-90.
22. Loscher W (1997) Animal models of intractable epilepsy. Prog Neurobiol 53:239-258.
23. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-632.
24. Morrow CS, Cowan KH (1988) Mechanisms and clinical significance of multidrug resistance. Oncology 2:55-63.
25. Munari C, Hoffmann D, Francione S, Kahane P, Tassi L, Lo Russo G, Benabid AL (1994) Stereo-electro-encephalo-graphy methodology: Advantages and limits. Acta Neurol Scand 152:56-67.
26. Nitsch C, Goping G, Klatzo I (1986) Pathophysiological aspects of blood-brain barrier permeability in epileptic seizures. In: Advances in Experimental Medicine and Biology (Schwarcz R, Ben-Ari Y, eds), pp 175-184. New York: Academic.
27. Owen A, Pirmohamed M, Tettey JN, Chadwick D, Kevin P (2001) Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 51:345-349.
28. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708-712.
29. Potschka H, Fedrowitz M, Loscher W (2001) P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. NeuroReport 12:3557-3560.
30. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32:281-294.
31. Reynolds EM (1987) Early treatment and prognosis of epilepsy. Epilepsia 28:97-106.
32. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T, Parmiani G (1990) Modulation of multidrug resistance by verapamil or mdr1 antisense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 46:727-732.
33. Rizzi M, Guiso G, Mulé F, Moneta D, Sperk G, Vezzani A, Caccia S (2001) Induction of MDR-1 by limbic seizures in mice: Relevance for drug resistance in epilepsy. Soc Neurosci Abstr 27:553.2.
34. + channels in the developing brain of genetically seizure-susceptible E1 mice. Neuroscience 48:285-291.
35. Schinkel AH, Smit JJM, van Tellinger O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riete HPJ, Berns AJM, Borst P (1994) Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
36. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
37. Sills GJ, Kwan P (2001) P-glycoprotein-mediated antiepileptic drug transport: A role in refractory epilepsy? Epilepsia 42 [Suppl 7]:83.
38. Sisodiya SM, Heffernan J, Squier MV (1999) Over-expression of P-glycoprotein in malformation of cortical development. NeuroReport 10:3437-3441.
39. Sisodiya SM, Lin W-R, Squier MV, Thom M (2001) Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 357:42-43.
40. Spreafico R, Battaglia G, Arcelli P, Andermann F, Dubeau F, Palmini A, Olivier A, Villemure JG, Tampieri G, Avanzini G, Avoli M (1998) Cortical dysplasia. An immunocytochemical study of three patients. Neurology 50:27-36.
41. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
42. Tishler DM, Weinberg K, Hinton DR, Barbaro N, Annett GM, Raffel C (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36:1-6.
43. Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91:8822-8826.
44. Zhang L, Ong WY, Lee T (1999) Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res 126:509-516.